Status:
ENROLLING_BY_INVITATION
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.
Lead Sponsor:
Mayo Clinic
Conditions:
Healthy Controls
Eligibility:
All Genders
4-21 years
Brief Summary
The purpose of this research is to understand the normal healthy response to immunological challenge by measuring circulating cytokine and chemokine levels before and after vaccinations in healthy chi...
Detailed Description
Children who experience seizures that cannot be stopped by traditional anti-seizure medications often suffer profound brain injury and intellectual disability. Indeed, many of these children do not su...
Eligibility Criteria
Inclusion
- Children 5-7 months of age receiving the 3rd scheduled dose of the diphtheria, tetanus, pertussis, inactivated polio, Haemophilus influenzae type b, and pneumococcal conjugate vaccine (DTap-IPV/Hib+PCV13).
- Children 10-18 months of age receiving the 1st scheduled dose of the measles, mumps, rubella, and varicella vaccine (MMR+VZV).
- Children 4-6 years of age receiving the 2nd scheduled MMR+VZV dose.
- Children and young adults receiving the annual flu vaccine or COVID vaccine
Exclusion
- History of autoinflammatory or autoimmune disease.
- History of genetic or metabolic disorder.
- History of hematological disorder.
- History of malignancy or active malignancy undergoing suppressive treatment.
- Blood donation or collection within 8 weeks of the study.
- Signs or symptoms consistent with severe infection at the time of first visit.
- Weight less than 6 kg in group 1, less than 7.5 kg for group 2, less than 12 kg for group 3.
Key Trial Info
Start Date :
August 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04112355
Start Date
August 16 2019
End Date
December 1 2025
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905